TAILSTORM HEALTH INC – FDA 483, Aug 28, 2026

During an inspection of Tailstorm Health, Inc. in Chandler, Arizona, conducted from August 17 to August 28, 2026, the FDA identified several significant operational deficiencies. As an outsourcing facility, the firm is subject to the regulatory framework of the Federal Food, Drug, and Cosmetic Act. The primary violations center on the failure to maintain sterile conditions during the processing of injectable and inhalation drugs. Key issues include cleanroom certifications that do not reflect routine production environments, inadequate sterilization protocols for equipment and products, and a lack of routine monitoring using biological indicators. Investigators also discovered equipment maintenance failures, such as leaking valves and stagnant water within production systems, which pose a risk of contamination. Additionally, the facility failed to properly investigate findings of foreign particles in drug vials, out-of-tolerance laboratory scales, and temperature excursions in the warehouse. Laboratory controls were also deemed insufficient, particularly regarding the testing of nitrogen gas and high-risk chemical components like Propylene Glycol. While these observations do not constitute a final agency determination, the firm is required to submit a detailed response to the FDA outlining its corrective actions or objections to ensure future compliance with safety and quality standards.